The Myeloma Trial Finder lists clinical trials which are currently recruiting in the UK. If you are thinking about joining a clinical trial you should talk to your healthcare team to find out if this is a suitable option for you.

It provides information about clinical trials in the UK. Trials included are not necessarily endorsed by Myeloma UK.

Further information can be found on our website under Clinical Trials and Novel Drugs or if you would like to speak to someone please call the Myeloma UK infoline on 0800 980 3332

Recruitment to clinical trials may be paused at some hospitals due to the COVID-19 pandemic. Your healthcare team can provide additional details about recruitment to clinical trials in your area.

There are currently 26 open trials. In 111 locations

What is a Clinical Trial?

Step 2: Choose a Trial

There are currently 26 open trials

Step 3: View Details

Trial Title:

Isatuximab in combination with lenalidomide and dexamethasone for high-risk smouldering myeloma (ITHACA)


Lenalidomide (Revlimid®)

Myeloma stage:


Trial phase:




This trial is investigating how the safety and effectiveness of isatuximab (Ninlaro), lenalidomide (Revlimid) and dexamethasone compares to lenalidomide and dexamethasone for the treatment of high-risk smouldering myeloma.



Leicester Royal Infirmary, Leicester

Who can enter the study?

Who can enter the study?:

Patients with high-risk smouldering myeloma who have been diagnosed less than five years ago.

What's involved?

What's involved?:

Patients will be randomised to receive either isatuximab, lenalidomide, and dexamethasone or lenalidomide and dexamethasone.

Patients will be required to attend outpatient clinics for regular check-ups and blood tests.

The duration of the trial is approximately 10 years, including a 28-day screening period, followed by an up to 36-month treatment period, and a follow-up period of approximately 7 years.


Clinical Information

Clinical Information
(for Medical Professionals):

A randomized, single-blinded, phase III trial to evaluate the safety and efficacy of isatuximab, lenalidomide and dexamethasone for the treatment of high-risk smouldering myeloma. For more information click here.


Find out more about Myeloma UK:


Do you want to talk to someone? Call our myeloma Infoline